{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:29:14Z","timestamp":1791559754832,"version":"4.3.4"},"reference-count":32,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.2967\/jnumed.122.264816","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T21:10:29Z","timestamp":1668114629000},"page":"542-548","source":"Crossref","is-referenced-by-count":10,"title":["Cure of Disseminated Human Lymphoma with [<sup>177<\/sup>Lu]Lu-Ofatumumab in a Preclinical Model"],"prefix":"10.2967","volume":"64","author":[{"given":"Kyuhwan","family":"Shim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Longtine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane S.","family":"Abou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Hoegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Laforest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.J.","family":"Thorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2023040307200718000_64.4.542.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"2023040307200718000_64.4.542.2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120561"},{"key":"2023040307200718000_64.4.542.3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol."},{"key":"2023040307200718000_64.4.542.4","doi-asserted-by":"crossref","unstructured":"Sarbisheh EK Price E . The radiopharmaceutical chemistry of the radioisotopes of lutetium and yttrium. In: Lewis JS Windhorst AD Zeglis BM , eds. Radiopharmaceutical Chemistry. Springer; 2019:359\u2013370.","DOI":"10.1007\/978-3-319-98947-1_20"},{"key":"2023040307200718000_64.4.542.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.253450"},{"key":"2023040307200718000_64.4.542.6","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)."},{"key":"2023040307200718000_64.4.542.7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 vipivotide tetraxetan: first approval","volume":"26","author":"Keam","year":"2022","journal-title":"Mol Diagn Ther."},{"key":"2023040307200718000_64.4.542.8","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"2023040307200718000_64.4.542.9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2967\/jnumed.117.203299","article-title":"Evaluation of next-generation anti-CD20 antibodies labeled with 89Zr in human lymphoma xenografts","volume":"59","author":"Yoon","year":"2018","journal-title":"J Nucl Med."},{"key":"2023040307200718000_64.4.542.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.07.044"},{"key":"2023040307200718000_64.4.542.11","unstructured":"Stabin M . Fundamentals of Nuclear Medicine Dosimetry. Springer; 2008:77\u2013119."},{"key":"2023040307200718000_64.4.542.12","first-page":"1","article-title":"Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP publication 53. ICRP publication 106. Approved by the Commission in October 2007","volume":"38","year":"2008","journal-title":"Ann ICRP."},{"key":"2023040307200718000_64.4.542.13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s11307-021-01594-0","article-title":"Bioluminescent tumor signal is mouse strain and pelt color dependent: experience in a disseminated lymphoma model","volume":"23","author":"Hoegger","year":"2021","journal-title":"Mol Imaging Biol."},{"key":"2023040307200718000_64.4.542.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0039"},{"key":"2023040307200718000_64.4.542.15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/1874471011306010004","article-title":"Biodistribution and dosimetry of 177Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma","volume":"6","author":"Repetto-Llamazares","year":"2013","journal-title":"Curr Radiopharm."},{"key":"2023040307200718000_64.4.542.16","unstructured":"A comparative analysis of Rag2\/Il2rg (R2G2) and NSG radiosensitivity. ENVIGO website. https:\/\/insights.envigo.com\/r2g2-radiation-study-data-a-comparative-analysis-of-r2g2-and-nsg-radiosensitivity. Published 2017. Accessed December 13, 2022."},{"key":"2023040307200718000_64.4.542.17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910450318"},{"key":"2023040307200718000_64.4.542.18","doi-asserted-by":"crossref","unstructured":"Havlena GT Kapadia NS Huang P . Cure of micrometastatic B-cell lymphoma in a SCID mouse model using 213Bi anti-CD20 monoclonal antibody. J Nucl Med. August 18, 2022 [Epub ahead of print].","DOI":"10.2967\/jnumed.122.263962"},{"key":"2023040307200718000_64.4.542.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.160"},{"key":"2023040307200718000_64.4.542.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.08.024"},{"key":"2023040307200718000_64.4.542.21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MNM.0000000000000501","article-title":"Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma","volume":"37","author":"Yadav","year":"2016","journal-title":"Nucl Med Commun."},{"key":"2023040307200718000_64.4.542.22","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1038\/s41598-022-10139-6","article-title":"89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma","volume":"12","author":"Giesen","year":"2022","journal-title":"Sci Rep."},{"key":"2023040307200718000_64.4.542.23","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-21-0791","article-title":"Targeted radionuclide therapy with low and high-dose lutetium-177-labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model","volume":"21","author":"Ertveldt","year":"2022","journal-title":"Mol Cancer Ther."},{"key":"2023040307200718000_64.4.542.24","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-21-1533","article-title":"Radioimmunotherapy targeting Delta-like ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity","volume":"28","author":"Tully","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2023040307200718000_64.4.542.25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/acs.chemrev.8b00294","article-title":"Radioactive main group and rare earth metals for imaging and therapy","volume":"119","author":"Kostelnik","year":"2019","journal-title":"Chem Rev."},{"key":"2023040307200718000_64.4.542.26","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2967\/jnumed.119.237230","article-title":"177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin\u2019s lymphoma","volume":"61","author":"Malenge","year":"2020","journal-title":"J Nucl Med."},{"key":"2023040307200718000_64.4.542.27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/ejh.13139","article-title":"Combination of 177Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin\u2019s lymphoma","volume":"101","author":"Repetto-Llamazares","year":"2018","journal-title":"Eur J Haematol."},{"key":"2023040307200718000_64.4.542.28","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0554"},{"key":"2023040307200718000_64.4.542.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.115170"},{"key":"2023040307200718000_64.4.542.30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8008"},{"key":"2023040307200718000_64.4.542.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1413-9"},{"key":"2023040307200718000_64.4.542.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612770"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T14:21:21Z","timestamp":1680531681000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.2967\/jnumed.122.264816"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264816","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]}}}